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Abstract. The L1 adhesion molecule is a member of 
the immunoglobulin superfamily shared by neural and 
immune cells. In the nervous system L1 can mediate 
cell binding by a homophilic mechanism. To analyze its 
function on leukocytes we studied whether L1 could in- 
teract with integrins. Here we demonstrate that VLA-5, 
an RGD-specific fibronectin receptor on a wide variety 
of cell types, can bind to murine L1. Mouse ESb-MP 
cells expressing VLA-5 and L1 could be induced to ag- 
gregate in the presence of specific mAbs to CD24 
(heat-stable antigen), a highly and heterogeneously gly- 
cosylated glycophosphatidylinositol-linked differentia- 
tion antigen of hematopoietic and neural cells. The ag- 
gregation was blocked by both mAbs to L1 and VLA-5, 
respectively. Aggregation was blocked also by a syn- 
thetic RGD-containing peptide derived from the Ig- 
domain VI of the L1 protein. ESb-MP subclones with 
low L1 expression could not aggregate. In heterotypic 
binding assays mouse bone marrow cells could adhere 
in an Ll-dependent fashion to platelets that expressed 
VLA-5. Also purified L1 coated to polystyrene beads 
could bind to platelets. The binding of Ll-beads was 
again inhibited by mAbs to L1 and VLA-5, by soluble 
L1 and the L1-RGD peptide in a dose-dependent man- 
ner. Thymocytes or human Nalm-6 tumor cells express- 
ing VLA-5 could adhere to affinity-purified L1 and to 
the Ll-derived RGD-containing peptide coated to glass 
slides. The adhesion was strongly enhanced in the pres- 
ence of Mn2÷-ions and blocked by mAbs to VLA-5. We 
also demonstrate a direct L1-VLA-5 protein interac- 
tion. Our results suggest a novel binding pathway, in 
which the VLA-5 integrin binds to L1 on adjacent cells. 
Given its rapid downregulation on lymphocytes after 
induction of cell proliferation, L1 may be important in 
integrin-mediated and activation-regulated cell-cell in- 
teractions. 
EUKOCYTE function is crucially dependent on cell-adhe- 
sion which provides the necessary mechanical sta- 
bility for cell-cell contact but may also deliver sig- 
nals  from  the  micro-environment.  Integrins  have  been 
shown  to  be  important  activation-dependent  adhesion 
molecules that possess also signaling potential (for review 
see reference 37). On leukocytes, integrins are involved in 
cell-cell and cell-extracellular matrix interactions and play 
a role in physiological processes such as the regulation of 
lymphocyte responses to antigenic stimulation, the recir- 
culation into lymphoid tissues or the extravasation at sites 
of inflammation (for reviews see reference 17, 78). The 132- 
integrins LFA-1 (aL132) and Mac-1 (aM~2) and the et4- 
integrins participate in distinct mechanisms for leukocyte- 
endothelial and leukocyte-leukocyte binding (for review 
see reference 20).  Several members of the Ig superfamily 
have been identified as cell surface ligands for these inte- 
grins. LFA-1, can bind to intercellular cell adhesion mole- 
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cule (ICAM)-I l or ICAM-2 on the surface of stimulated 
or unstimulated endothelial cells or to ICAM-3 on lym- 
phocytes. ICAM-1 and ICAM-2 are not restricted to en- 
dothelial cells but are also expressed by leukocytes and are 
involved in many leukocyte functions including the recog- 
nition of target cells by cytotoxic T  lymphocytes and the 
collaboration of T- and B-lymphocytes. The et4-integrins 
VLA-4  0x4131) and  LPAM-1  (a4137) mediate  leukocyte 
adhesion to the vascular cell adhesion molecule VCAM-1 
(65),  and the addressin MAdCAM-1  (9).  These interac- 
tions are important for the migration and recirculation of 
lymphocytes from the blood stream into lymphoid organs. 
VLA-4 can also support the binding of leukocytes to fi- 
bronectin involving an LDV peptide motif in the HeplI/ 
IIICS region of fibronectin (CS-1 peptide) (30, 48). 
Other integrins of the VLA family promote the binding 
of  leukocytes  to  extracellular  matrix  components  like 
laminin, collagen or fibronectin (for review see  34,  36). 
The VLA-5 integrin is the classical fibronectin receptor 
and it binds to fibronectin via an RGD-sequence in the 
1.  Abbreviations  used  in  this  paper:  2-ME,  2-mercaptoethanol;  BOG, 
I~-octylglucoside; GPI,  glycosylphosphatidylinositol; ICAM,  intercellular 
adhesion molecule; PE, phycoerythrin. 
© The Rockefeller  University  Press, 0021-9525/95/12/1881/11 $2.00 
The Journal of Cell Biology,  Volume 131, Number 6, Part 2, December 1995 1881-1891  1881 cell binding domain in the center of the molecule which is 
close to the COOH terminus of the tenth type III repeat of 
fibronectin  (59,  67).  VLA-5  is  expressed  on  many  cell 
types including fibroblasts, epithelial and endothelial cells, 
platelets, thymocytes and T lymphocytes and is involved in 
the  regulation  of cell adhesion  and  matrix assembly  (3, 
38), in cell migration beneath stromal cells (63), in the ad- 
hesion and migration of neural crest cells (7, 13) and has 
been implicated to influence tumor growth (29, 71, 77). An 
alternative cellular ligand for VLA-5 has not been identified. 
The L1 cell adhesion molecule is a 200-kD transmem- 
brane glycoprotein belonging to the immunoglobulin su- 
perfamily (64, 69). Structurally related antigens that prob- 
ably represent homologous molecules have been identified 
in other species including rat (NILE) (56, 61), chick (Ng- 
CAM) (16), drosophila (neuroglian) (10), and human (46, 
86). L1 was first described in the nervous system and ap- 
pears to mediate binding by distinct mechanisms: (a) ho- 
motypic binding involving L1-L1 interactions (40, 41, 75); 
(b) assisted homophilic binding between L1 and L1-NCAM 
complexes at the surface of adjacent cells (40, 41); and (c) 
heterotypic  binding  of  which  the  interaction  with  the 
axon-associated CAM axonin-1 (53) and the chondroitin 
sulfate proteoglycan phosphacan (62) are well character- 
ized. Further ligands for L1 have been postulated but have 
not been identified. The L1 molecule plays an important 
role in cell migration and axon outgrowth in the nervous 
system. L1 expression was also found on normal and trans- 
formed cells of hematopoietic origin (50,  51). Bone mar- 
row cells, mature thymocytes and the majority of periph- 
eral B  and T  lymphocytes express the antigen.  Whereas 
the function of L1 in the nervous system is well established 
its role in the adhesion of leukocytes is not known. 
Here we report that the L1 adhesion molecule as well as 
an RGD-containing peptide derived from the L1 sequence 
can serve as a ligand for VLA-5. In the presence of mAbs 
to CD24, a highly glycosylated glycophosphatidylinositol- 
linked differentiation antigen, mouse ESb-MP cells could 
aggregate in an L1 and VLA-5-dependent manner.  Our 
results suggest that VLA-5 and L1 constitute a novel bind- 
ing pathway involved in  homotypic and  heterotypic cell 
adhesion. Given its rapid downregulation on lymphocytes 
and neutrophils after cell activation (35), L1 may be im- 
portant in integrin-mediated and activation-regulated in- 
teractions of leukocytes during the immune response. The 
VLA-5-L1  binding  pathway  may  also  be  important  in 
other cell--cell interactions. 
Materials and Methods 
Cell Culture 
The murine bend3 endothelioma cell line was kindly provided by Dr. W. 
Risau (Max-Planck Institut Bad Nauheim, Germany) and was maintained 
in DME  with high Glucose (Life Technologies, Eggenstein, Germany) 
containing 10% FBS (low endotoxin; Life Technologies). The monocytic 
tumor cell line ESb-MP was cultivated in RPMI 1640 supplemented with 
10%  FBS, 2-mercaptoethanol (2-ME), Hepes, and Glutamine as previ- 
ously described (76). The isolation and characterization of ESb-MP sub- 
clones with L1 hi or L1 I° expression has been described previously (50, 51). 
All cells were kept at 37°C,  5%  CO2, and 100%  humidity. Thymocytes 
were collected from 6~-wk-old DBA/2 or Balb/c mice. Platelets were iso- 
lated from mouse blood as described  (2).  Residual erythrocytes were 
lysed by brief incubation in  155  mM NH4C1,  0.1  mM EDTA,  10 mM 
KHCO3 solution followed by washing of the cells. Purified platelets ex- 
pressed vonWillebrand factor and P-selectin as described (2). The human 
Nalm-6 pre-B-cell line was obtained from Dr. R. Schwarz-Albiez (DKFZ, 
Heidelberg, Germany). 
Antibodies 
mAbs 79  and M1.69  against mouse CD24 have been described before 
(42); mAbs 30G12 against mouse CD45; MK2.7 against VCAM-1, YN.1/ 
1.7 against ICAM-1,324 and 555 against the L1 adhesion molecule, 12-15 
against mouse CD2, mAbs PS/2, and 5/3 against tx4 integrins were also de- 
scribed before (4, 51). mAbs FD441.8 (TIB 213) and FD 18.5 recognizing 
the a-chain of LFA-1 and M1/70.15.11.5  (TIB 128) against the a-chain of 
Mac-1 were obtained from American Type Culture Collection (Rockville, 
MD)  and were described before (2,  51). mAb 5H10-27 (MFR5)  against 
CD49e  (mouse a5)  (mAb a5(1))  was obtained  from Pharmingen (Di- 
anova,  Hamburg,  Germany).  HMa5-1  and  HMa5-2  (mAb c~5(2)) are 
blocking hamster mAbs against mouse a5 integrin (88). MAb RMV-7 is a 
blocking antibody to  mouse vitronectin receptor  on  lymphocytes (79). 
MAb RB40.34 recognizing mouse P-selectin (12) was a gift of D. Vestwe- 
ber (Max-Planck Institute ftir Immunbiologie, Freiburg, Germany). mAb 
EA-1 (39) against mouse a6-integrin was a gift of B. Imhof (Basel Institute 
for Immunology, Basel, Switzerland). The mAb to human VLA-5 (Sam-l) 
was obtained from Dianova. The anti-human CD24 mAb ML5 was ob- 
tained from Dr.  S.  Funderud (Raaium Hospital, Oslo, Norway).  mAbs 
were used in a purified form or as hybridoma supernatants. 
Peptides 
Peptides were synthesized using Fmoc strategy and purified by prepara- 
tive HPLC. They were characterized further by analytical HPLC and mass 
spectroscopy. The L1-RGD peptide was CWRGDGRDLQERGDSDK. 
For  control  the peptide  VAIYDDMESLPLTGT  was  used. The  cyclic 
peptide  GA*CRRETAWAC*GA has been reported  to inhibit specifi- 
cally human a5131-mediated cell binding to fibronectin (47).  The RGDS 
peptide was obtained from Sigma (Taufkirchen, Germany). Peptide-car- 
tier protein conjugates for cell adhesion were produced by crosslinking 
N-succinimidyl  3-(2-pyridyldithio)propionate  (SPDP)  activated  rabbit 
IgG with peptides via the NHz-terminal Cystein residue (4).  Unconju- 
gated IgG was used for control purposes in the binding assays. Peptide- 
carrier conjugates were coated to glass slides as described below. The cy- 
clic  RGD  peptide  66203  (cycloRGDfV)  that  inhibits preferentially av 
(Brooks et al., 1994) and 69601 (cycloRADfV) (control peptide) were ob- 
tained from Dr. A. Jonczyk (E. Merck, Darmstadt, Germany). 
Cytofluorography 
The staining of cells with saturating amounts of mAbs, either hybridoma 
supernatants or purified  antibodies, and phycoerythrin (PE)-conjugated 
goat antibodies to rat immunoglobulins (SERVA, Heidelberg, Germany), 
has been described elsewhere (50).  Stained  cells were  analyzed with  a 
FACScan fluorescence activated cell analyzer (Becton Dickinson, Heidel- 
berg, Germany). 
Affinity Purification of Cell Surface  Antigens 
L1 was purified by affinity chromatography on a mAb 324 column from 
lysates of ESb-MP cells or N2A neuroblastoma cells essentially as de- 
scribed elsewhere (35). CD2 was isolated from mouse thymocyte lysate on 
a mAb 12-15-sepharose column. The elution buffer contained 100 mM di- 
ethylamine/HC1, pH  11.5,  150  mM NaCl with 50  mM 13-octylglucoside 
(BOG).  Soluble  L1  from  mouse brain  was  a  gift of Dr.  G.  Kadmon 
(DKFZ, Heidelberg, Germany). VLA-5 was isolated from thymocyte ly- 
sate on a HMa5-1-sepharose column. The antigen was eluted with 0.2 M 
acetic  acid,  50 mM BOG,  500 mM NaCI  containing 2  mM CaCI2  and 
MgCI  2. Eluted fractions were neutralized and analyzed by ELISA with re- 
spective antibodies and by SDS-PAGE. Purified antigens were stored at 
-20°C.  For  coating to  polysterene beads  L1  antigen  (~150  txg/ml)  in 
BOG was incubated with the beads (SERVA) and the detergent was re- 
moved  by  dialysis  as  described  (35).  Remaining  binding  sites  were 
blocked by incubation with 1% BSA in PBS for 1 h. The density of coated 
L1  was determined by FACS analysis using biotinylated mAb 324 fol- 
lowed by Streptavidin-Phycoerythrin (Dianova). The soluble mouse CD2 
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part of the mouse ~ light chain) was a kind gift of R. Rutschmann (Basel 
Institute for Immunology, Basel, Switzerland). 
Homotypic Cell  Aggregation Assay 
For homotypic aggregation ESb-MP cells at 2 ×  106/ml were incubated in 
the presence of t0-50 l~g/ml of purified mAb 79 to mouse CD24 in com- 
plete RPMI 1640 medium for 30 min at room temperature in 1.5-ml Ep- 
pendorf tubes. Tubes were rotated headwise to keep cells in suspension. 
At the end of incubation time the cells in medium were transferred to 24- 
well tissue culture plates, were allowed to sediment for 5 min and were 
then scored for aggregation. 
Heterotypic Cell Binding  Assay 
For binding assays the bend3 endothelioma cells were grown to conflu- 
ency in LABTEK glass chamber slides (Nunc, Wiesbaden, Germany). For 
platelet binding experiments the platelets were stimulated with PMA (10 
ng/ml) for 10 min at room temperature, fixed with 2% formaldehyde, and 
adsorbed to LABTEK-slides for overnight at 4°C (2). Before the binding 
assay the slides were incubated in tissue culture medium containing 10% 
FBS to block residual binding sides. Cells or coated polysterene beads 
(2  x  106/ml or 4  ×  106/ml, respectively) in  HBSS containing 10 mM 
Hepes, 2 mM Ca  2÷ and Mg  z÷ (binding buffer) were incubated for 20 min 
at room temperature on the cell monolayer under constant shaking on a 
rotary platform (70-80 rpm). Slides were then dipped in PBS to remove 
unbound beads or cells, fixed with 2% glutaraldehyde and counted. 
For binding of ceils to purified L1 the antigen in BOG was diluted 1:10 
to 1:30 with 10 mM Tris-HCl, pH 8.0,150 mM NaC1 (TBS), and were then 
coated to LABTEK slides for 16 h  at 4°C.  Wells were blocked with 1% 
BSA  in  PBS  or  1%  ovalbumin in  TBS  for  2  h  at  room  temperature, 
washed with binding buffer and used for the assay. For binding, ceils (5-10 
×  106/ml)  were suspended in the same buffer and 0.2-ml aliquots were 
added to the coated slides. The binding assay was performed for 30 rain at 
room temperature without shaking and the slides were washed and fixed 
as described above. For antibody or peptide-blocking studies, cells were 
preincubated with purified antibody or peptides at the indicated concen- 
tration for 10 min at room temperature and then transferred to the cham- 
ber slides. For MnZ+-activation, the Ca  2+ and Mg  2+ ions in the buffer were 
substituted with 0.5 mM Mn  2÷. Cell binding was measured by counting six 
independent 10× fields by video microscopy using IMAGE 1.47 software. 
Biochemical Analysis 
SDS-PAGE and Western blotting procedures have been described previ- 
ously (40, 42, 54). Biotinylation of soluble L1 or the CD2-CK fusion pro- 
tein was performed at ~100 p.g/ml using a similar procedure as previously 
described for mAbs (35). Procedures for ELISA were also described be- 
fore (41). For the binding of biotinylated antigens to VLA-5 the affinity- 
Figure 1.  CD24 induced homotypic aggregation of ESb-MP cells. (A) ESb-MP cells (2 ×  106/ml ) were incubated under constant head- 
over head rotation for 30 min in the presence of increasing concentrations of the inducing CD24 mAb  (mAb 79) at room temperature. 
The cells were then transferred to a microtiter plate and photographed. (B) ESb-MP were activated for 30 min by mAb 79 (50 ~g/ml) in 
the presence or absence of the indicated mAbs to L1 (324 and 555), VLA-5 (HMet5-1), L1-RGD  peptide or a mAb to CD2 for control. 
(C) ESb-MP subclones with different L1 phenotype(L1 hi or L1 l°) were activated as described above. The phenotype of each subclone as 
assessed by FACS analysis is indicated. Bar, 83 txm. 
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by dilution (140) with 10 mM Tris-HC1, pH 8.0, 150 mM NaC1 containing 
1 mM of each Ca  2÷, Mg  2÷, and Mn  2÷ ions (TBS plus ions). Affinity-puri- 
fied  L1  or  CD2  were  coated  under  similar  conditions.  All  following 
washes and incubation steps with biotinylated L1 or CD2-CK fusion pro- 
tein (1 ixg/ml) were carried out in the same buffer. Bound biotinylated an- 
tigens were  detected  by  streptavidin-conjugated peroxidase  (Dianova) 
and 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic  acid) (Sigma) as sub- 
strate. 
Statistical Analysis 
Tests for statistical significance between the quantitative effects of differ- 
ent treatments were done using the Wilcoxon's rank sum test. Statements 
regarding differences are significant with a value ofp ~< 0.0043. 
Results 
LI-mediated Homotypic Aggregation of  ESb-MP Cells 
We have shown in earlier studies that ESb-MP cells form 
homotypic cell aggregates that can be blocked by Ll-spe- 
cific antibodies (40, 50). This spontaneous aggregation oc- 
curred within 3 h at 37°C and was not seen in Lll°-express  - 
ing subclones of ESb-MP cells that were obtained from the 
parental subline suggesting an important role for L1 in this 
process (50). We now show that strong homotypic aggre- 
gation in shorter time can be induced in the presence of 
mAbs  against  mouse  CD24.  Fig.  1 A  indicates  that  the 
CD24-specific mAb 79 caused aggregation within 30 min 
at 24°C in a dose-dependent manner. This effect was not 
dependent on the Fc-portion of the mAb since an isotype- 
matched  control  mAb  (30G12)  did  not  induce  aggrega- 
tion. Another mAb against CD24, i.e., M1.69, also caused 
aggregate formation (data not shown). 
To  examine  whether  the  CD24-induced  aggregation 
also  involved  L1,  blocking  studies  were  performed.  As 
summarized in Table I and depicted in Fig. 1 B, a mixture 
of Ll-specific mAbs (324 and 555) inhibited the aggrega- 
tion,  whereas  control mAbs against CD2  (12-15),  CD45 
(30G12), ICAM-1 (YN 1/1.7), VCAM-1 (MK2.7) showed 
no effect. Soluble L1 at 2 ~g/ml significantly reduced ag- 
gregate formation. Fig. 1 C indicates, that the Lll°-express  - 
ing subclones (subclones 5 and 12) in contrast to the L1 hi 
subclone 8  could  not  undergo  CD24-induced  homotypic 
aggregation although the levels of CD24 and VLA-5 (see 
betow) were comparable as judged by FACS analysis (not 
shown).  These  results  suggested,  that  CD24  mAbs  can 
drastically enhance  the Ll-mediated homotypic aggrega- 
tion of ESb-MP cells. 
ESb-MP Cell Aggregation Is Blocked by 
mAbs to VLA-5 
L1 has been shown to participate in homophilic and het- 
erophilic interactions (40, 53, 62). Since the homotypic ag- 
gregation of ESb-MP cells did not occur at 4°C (data not 
shown) we wondered whether the putative counter-recep- 
tor for L1  might be an integrin.  We  therefore  analyzed 
ESb-MP cells for integrin expression. As shown in Fig. 2 
A, ESb-MP cells expressed LFA-1, Mac-l, or4-, e~5-, et6-inte- 
grins,  and the vitronectin receptor aVS3  as revealed by 
FACS  staining  with  the  respective  mAbs.  When  these 
mAbs were tested for blocking capacity in the homotypic 
aggregation assay, only the two mAbs to VLA-5 showed 
A 
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Figure 2.  Integrin expression pattern of ESb-MP cells. (A) ESb- 
MP cells were stained with saturating  amounts of mAbs to the in- 
dicated  antigens  followed  by PE-conjugated second antibodies 
and then analyzed for fluorescence.  (B) Analysis of VLA-5 ex- 
pression on mouse platelets,  bend3 endothelioma cells, and thy- 
mocytes. Arrows indicate the right border of background fluores- 
cence (second antibody only). 
significant  inhibition  (Table  I  and  Fig.  1  B).  All  other 
mAbs to integrins  or their respective cellular ligands  as 
listed in Table I had no effect. 
An Ll-derived RGD-containing Peptide Inhibits 
Homotypic Aggregation 
VLA-5  (etSI31) is  a  fibronectin receptor and  binds  to  an 
RGD  site  in  fibronectin.  We  reasoned  that  if  VLA-5 
would be a  counter-receptor for L1  it might bind to the 
two RGD sites known to be present in close proximity in 
the Ig-domain VI of the L1 molecule (64).  We therefore 
examined the effects of RGD-containing peptides on the 
CD24 induced aggregation of ESb-MP cells. As shown in 
Table I the peptide RGDS at 2 mg/ml effected the homo- 
typic aggregation only weakly. In contrast, the RGD pep- 
tide  CWRGDGRDLQERGDSDK derived from the  6th 
domain of L1 showed a good blocking effect that was close 
dependent.  At a  concentration of 5 mg/ml peptide there 
was virtually no aggregation observed even after longer in- 
cubation times at 37°C although the cells remained viable 
as judged  by tryphan blue  exclusion.  A  control  peptide 
VAIYDDMESLPLTGT  in  the  same  buffer  as  the  L1- 
RGD peptide and tested in the same range of concentra- 
tion  (1-5  mg/ml) had  no effect on the  aggregation. The 
cyclic peptide  GA*CRRETAWAC*GA  which  has been 
reported to inhibit specifically human c~5[M-mediated cell 
binding to fibronectin (47)  also showed an inhibitory el- 
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Aggregation of ESb-MP Cells by mAbs and Peptides 
Reagent  Antigen  Homotypic aggregation 
Antibodies 
Medium  -  + + + + 
mAb 30G12  CD45  + + + + 
mAb 12-15  CD2  ++++ 
mAbs 324+555  LI  + 
mAb MFR5  et5  + 
mAb MHc~5-2  a5  + 
mAb EA- 1  a6  + +  + + 
mAb RMV-7  aV  + + + + 
mAb FD18-5  LFA-1  + + + + 
mAb TIB213  LFA-1  + + + + 
mAb TIB 128  Mac- 1  + + + + 
mAb 5/3  a4  + + + + 
mAb P/S2  ct4  + + + + 
mAb YN 1/1.7  ICAM-!  ++++ 
mAb MIC2/4  ICAM-2  + + + + 
mAb MK2/7  VCAM-1  + + +  + 
Peptides 
RGDS 2 mg/ml  + + + 
L1-RGD 1 mg/ml  ++ 
LI-RGD 2 mg/ml  + 
LI-RGD 5 mg/ml 
control peptide 2 mg/ml  + +  + + 
GA*RRETAWAC*GA 1 mg/ml  + 
cycloRGDfV(66203) 2 mg/ml  + + + + 
cycloRADfV(69601) 2 mg/ml  + +  + + 
Cells at 2  ×  106/ml were induced to aggregate in the presence  of 50 Ixg/mI mAb 79. 
Blocking antibodies were used at the concentration of 10 Ixg/ml. Peptides were used at 
the indicated concentrations.  Note that all mAbs shown in this table can bind to ESb- 
MP ceils  as revealed by fluorescent  staining  except  for the  mAb to VCAM-I  for 
which the cells are negative. Data are compiled from >t0 experiments  in which each 
antibody  was tested  at least twice for inhibition.  Aggregation  scores are:  -  all ceils 
free;  +  10-20% cells aggregated;  + +  20-50% cells aggregated;  + + +  50-75% cells 
aggregated;  + + + + nearly all cells in aggregates. 
fect in the aggregation assay (see Table I). In contrast, a 
cyclic RGD peptide that was shown to be specific for av- 
integrins (15) and a cyclic control peptide had no effect. 
Heterotypic Binding of Bone Marrow Cells to Platelets 
Involves VLA-5 
The homotypic aggregation studies had suggested a poss  i- 
ble  interaction  of VLA-5 with L1  on adjacent cells  as  a 
novel  mechanism  of  cell-cell  binding.  We  examined 
whether this mechanism might also be effective in hetero- 
typic cell adhesion. First we studied the binding of bone 
marrow cells (expressing L1; reference 50) to platelets that 
expressed  VLA-5  (see  Fig.  2  B)  but  no  L1  (data  not 
shown) and that had been immobilized to glass slides.  Fig. 
3 shows that the bone marrow cells could bind to the plate- 
tet monolayer and this binding was completely blocked by 
a mAb to P-selectin in agreement with previous results (2). 
Both mAbs to L1 and VLA-5, respectively, were also able 
to block the  binding by ~40-70%  whereas  control anti- 
bodies could not (Fig. 3). 
We  also  analyzed the  binding  of ESb-MP  cells  (L1 hi) 
and  L1  l°  subclones  to  the  platelet  monolayer.  ESb-MP 
cells  bound well whereas the binding of L1  l° subclones 5 
and 12 was strongly reduced (65  and 50%, respectively). 
Both mAbs to L1 and VLA-5, respectively, were able to 
block the binding of ESb-MP cells to platelets  by ,-,~25% 
whereas control antibodies could not (data not shown). As 
BIndIng of bone  marrow cells to platelets 
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Figure  3.  Binding  of  bone 
marrow  cells  to  platelets. 
Platelets  were  immobilized 
to  LABTEK chamber  glass 
slides  after  treatment  with 
PMA and formaldehyde fixa- 
tion.  Bone marrow cells  at 
2  x  106/ml were  allowed to 
bind to the platelet monolayer 
in the presence or absence of 
the indicated antibodies. Un- 
der these conditions ~25% of 
input cells bind to the mono- 
layer. After cell binding the 
slides were washed, fixed in 
glutaraldehyde,  and  bound  cells were  counted.  Data  are  ex- 
pressed as mean values -+ SE. Three  independent  experiments 
were done with similar results. Area = 0.4 mm  2. 
expected, the cell binding was also blocked in the presence 
of the mAb to P-selectin'(2). Collectively, the data from 
both  types  of binding  experiment  suggested  that  in  the 
heterotypic binding of bone marrow cells or ESb-MP cells 
to platelets the VLA-5/L1 binding pathway was active in 
addition to the P-selectin-ligand interaction. 
L1-Beads Bind to Platelets via VLA-5 
We  next  investigated  whether  affinity-isolated L1  could 
mediate binding to platelets via VLA-5. L1 was purified by 
affinity chromatography from ESb-MP or N2A neuroblas- 
toma cell lysate, respectively. As shown in Fig. 4 A, the pu- 
rified antigen showed the expected bands of 200 and 150 
kD characteristic for L1 and its subfragment. The L1 anti- 
gen was adsorbed to polysterene beads and as shown in 
Fig. 4 B could be detected by FACS analysis using Ll-spe- 
cific mAbs. We  examined  the  binding  of the  Ll-coated 
beads to platelets expressing VLA-5. Fig. 5 A  shows that 
the  L1  beads  bound  well  to  the  immobilized  platelets 
whereas control beads that had been coated with BSA did 
not bind. The binding was completely blocked by mAbs to 
L1 and to a lesser extent by mAbs to VLA-5. Control anti- 
bodies to CD2 or LFA-1 did not have an effect. The bind- 
ing of L1 beads to platelets was significantly reduced in the 
presence of soluble L1 antigen. It was also blocked in the 
presence  of the  L1-RDG  peptide  in  a  dose-dependent 
manner whereas a control peptide had no effect. 
Binding of L1-Beads to Bend3 Enclothelioma Cells 
The murine bend3 endothelioma cells expressed VLA-5 as 
revealed  by FACS analysis  (see  Fig. 2 B).  Since we ob- 
served previously that L1 beads could bind to bend3 en- 
dothelioma cells (35) we investigated a  possible involve- 
ment of the VLA-5/L1 binding pathway in this interaction. 
As expected, the Ll-coated beads could bind to bend3 en- 
dothelioma cells in a specific fashion and this binding was 
inhibited by mAbs to L1 but not by control mAbs (Fig.  5 
B).  In contrast to the  platelet  binding experiment,  both 
mAbs to VLA-5 and the L1-RGD peptide were unable to 
block the binding. An inhibitory effect of the VLA-5 mAbs 
was also not seen after activation of endothelial cells with 
LPS for 4 h or when the binding assay was performed in 
the presence of Mn  2+ ions to activate the VLA-5 integrins 
(data not shown). 
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To analyze whether VLA-5 was expressed on the lumi- 
nal surface of the cells fluorescent staining of the bend3 
monolayer with specific mAbs was performed. Significant 
staining could be detected (data not shown) ruling out the 
possibility that VLA-5 was not accessible for the binding. 
Thus, we concluded that VLA-5 on the luminal site was 
functionally  not active in bend3 ceils. Importantly, the ex- 
periments  indicated  that  bend3  endothelioma  cells  ex- 
pressed another ligand for L1 distinct from VLA-5. 
Purified L1 and the L1-RGD Peptide Support 
Cell Binding 
We next studied whether purified L1  antigen or the  L1- 
RGD peptide could mediate the adhesion of cells. The pu- 
rified L1  was coated to glass slides and residual binding 
sites were blocked before the assay. We analyzed the bind- 
ing ability of thymocytes that expressed VLA-5 (see Fig. 2 
B). As shown in Fig. 6 A, thymocytes showed weak bind- 
ing to  the  immobilized L1  that  was  however  enhanced 
when the cells were activated in the presence of 0.5 mM 
Figure 4.  Characterization of purified L1 adhesion molecule. (A) 
Affinity-purified L1  antigen was  analyzed by SDS-PAGE fol- 
lowed by silver staining or transferred to nitrocellulose and de- 
tected by Western blotting using mAb 324. The same material 
was also analyzed by ELISA using mAb 324 hybridoma superna- 
tant or tissue culture medium for control. (B) Coating of purified 
L1 to polysterene beads and FACS analysis of the beads using bi- 
otinylated mAb 324 specific for L1 and biotinylated mAb 79 to 
CD24 (for control) followed  by Streptavidin-PE. Stained beads 
were analyzed by FACscan analysis. 
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Figure  5.  Binding  of  L1- 
coated polysterene beads to 
platelets and bend3 endothe- 
lioma  cells.  (A)  Ll-beads 
were  allowed  to  bind  to 
platelets immobilized to LAB- 
TEK  chamber  glass  slides. 
The assay was carried out in 
the  presence  or  absence  of 
mAbs, peptides or soluble L1 
at  the  indicated  concentra- 
tion  at  room  temperature. 
For L1 blocking a mixture of 
mAbs 324 and 555 was used. 
(B)  Ll-beads  were  allowed 
to  bind  to  bend3  endothe- 
lioma  cells  grown  in  LAB- 
TEK  chamber  glass  slides. 
The assay was carried out in 
the  presence  or  absence  of 
mAbs, or peptides used at 0.7 
mg/ml at room temperature. 
For L1 blocking a mixture of 
mAbs 324 and 555 was used. 
Data are expressed as mean 
values ±  SE. Three indepen- 
dent  experiments  for  each 
type  of  binding assay  were 
carried  out  with  similar re- 
suits. Area = 0.4 mm  2. 
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Figure 6.  Binding of thymocytes to purified L1 or the L1-RGD peptide. Affinity-purified L1 antigen in BOG or the L1-RGD peptide 
coupled to carrier IgG (1 mg/ml) were coated to LABTEK chamber glass slides. Thymocytes in HBSS/10 mM Hepes containing 2 mM 
of each Ca  2÷ and Mg  z÷ (stripped bars) or, alternatively, in the presence of 0.5 mM Mn  2÷ (solid bars) were tested for binding. Data are 
expressed as mean values +_ SE. Three independent experiments with similar results were done. Area =  0,4 mm  2. 
Mn  2÷ ions. The ESb-MP cells also showed weak binding to 
immobilized L1 that was enhanced by Mn  2÷ treatment of 
the cells (data not shown). However, due to the ability of 
these cells to adhere to glass the background binding was 
much higher than with thymocytes. 
To demonstrate direct binding of cells to the L1-RGD 
site the peptide CWRGDGRDLQERGDSDK was conju- 
gated to rabbit IgG as carrier and coated to glass slides in 
increasing concentrations. As shown in Fig. 6 B  the  L1- 
RGD  peptide  was  very potent  in  promoting thymocyte 
adhesion which was again strongly enhanced by Mn  >  acti- 
vation. Normal IgG (nonconjugated) alone could not sup- 
port cell adhesion. When the assay was carried out in the 
presence of Mn  2+  ions the binding of thymocytes to the 
L1-RGD-IgG was inhibited by both mAbs to VLA-5 as 
well  as  by the  mixture  of L1  mAbs  but  not by control 
mAbs, respectively (Fig.  6 C). Additional ELISA data in- 
dicated that the mixture of L1 mAbs were indeed able to 
bind to the immobilized L1-RGD-IgG but not to the con- 
trol IgG (data not shown). 
We also investigated whether L1 or the immobilized L1- 
RGD peptide could promote the binding of human Nalm-6 
cells  that are known to express VLA-5 (63).  Nalm-6 cells 
could bind both to the L1 glycoprotein as well as to the L1- 
RGD  peptide  after  Mn  2÷  activation.  The  binding  was 
blocked by mAb Sam-1 against human VLA-5 but not by 
a  control mAb to human CD24 (Fig. 7).  This suggested, 
that  L1  could promote  cell  binding  even  across  species 
barriers. 
Binding of  human Nalm 6-cells 
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Figure 7.  Binding of human Nalm-6 cells to purified L1 and the 
L1-RGD peptide. The L1 antigen in BOG and the L1-RGD pep- 
tide coupled to carrier IgG (1 mg/ml) were coated to LABTEK 
chamber glass slides. Purified CD24 (HSA) or normal unconju- 
gated IgG served as control antigens. Human Natm-6 pre-Bcells 
in HBSS/10 mM Hepes containing 0.5 mM Mn  2+ were tested for 
binding in the presence or absence of the indicated antibodies. 
Data are expressed as mean values _+ SE. Two independent ex- 
periments with similar results were done. Area =  0.4 mm  2. 
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L1-VLA-5  interaction  by 
ELISA. Biotinylated L1 was 
allowed  to bind  to immobi- 
lized CD2 (top), L1 (middle), 
or  VLA-5  (bottom)  in  the 
presence or absence of diva- 
lent  cations  (1  mM  of each 
Ca  2+, Mg  2+, and Mn  2+ ions). 
EDTA  and  EGTA  were 
used at a final concentration 
of 10 mM. The presence  of 
coated CD2 on the plate was 
verified by ELISA using the 
CD2  mAb  12-15. Biotiny- 
lated mAb 79 (10 ~zg/ml) was 
used  as  control  for nonspe- 
cific  binding.  Data  are  ex- 
pressed  as  mean  values  of 
triplicate determinations.  SE 
of the mean was less than 5% 
and  is  not  indicated.  Three 
independent experiments  with 
similar results were done. 
Demonstration of a Direct VLA-5-L1 Interaction 
To demonstrate  a  direct interaction  of VLA-5 and L1 an 
ELISA-based assay was employed. Soluble L1 was biotin- 
ylated and allowed to interact with immobilized VLA-5 in 
the  presence  of divalent cations.  As shown in Fig.  8, the 
soluble L1 was able to bind to immobilized VLA-5 or L1 
antigen.  The  heterophilic  binding  to VLA-5 was  depen- 
dent on divalent cations since it was not seen in the presence 
of EDTA/EGTA. In contrast, the homophilic L1-L1 bind- 
ing was rather  insensitive  to EDTA/EGTA  treatment  in 
agreement with the notion that the L1-L1 binding is Ca and 
Mg independent.  In the presence of the L1-RGD peptide 
(at 500 p~g/ml) the binding of L1 to VLA-5 was inhibited 
by  ~80%.  Biotinylated  L1  did  not  bind  to  immobilized 
CD2.  Conversely,  a  biotinylated  CD2-CK fusion  protein 
was unable to bind VLA-5 (data not shown). These results 
confirmed  the  functional data  on a  level of protein-pro- 
tein interaction. 
Discussion 
The analysis of homotypic cell aggregation, either sponta- 
neous or induced, has been helpful for the elucidation of 
general  adhesion  mechanisms.  For the  integrin-mediated 
homotypic aggregation of lymphocytes the interaction  of 
LFA-1 with ICAMs and the tx4-integrin-mediated binding 
pathway have been identified  (18).  A  counter  ligand  for 
~4-integrins on lymphocytes has not been found, and there 
is  suggestive  evidence  that  a  homophilic  ~4-tx4  integrin 
binding may be involved (4, 68). In the present report we 
analyzed the  homotypic aggregation induced  in ESb-MP 
cells by treatment with mAbs to the glycosylphosphatidyl- 
inositol  (GPI)-anchored molecule  CD24.  These  cells  can 
undergo  spontaneous  aggregation that  occurs slowly, re- 
quires  low  divalent  cation  concentrations  and  is  com- 
pletely blocked by polyclonal antibodies to L1 (40, 50). In 
the presence of mAbs to CD24 the aggregation was drasti- 
cally increased  and was detectable  in much shorter time. 
The available data suggested a novel mechanism of homo- 
typic  cell  binding  by  VLA-5  integrin  and  L1  via  RGD 
epitope(s)  which  were  also  involved  in  the  heterotypic 
binding of bone marrow cells or ESb-MP cells to immobi- 
lized platelets. 
Additional  proof for a  VLA-5-L1 binding came from 
studies  in  which  the  purified  L1  antigen  was  coated  to 
polysterene beads or immobilized to glass slides. In the lat- 
ter case a VLA-5-mediated binding to L1 as well as to the 
Ll-derived RGD peptide was seen with mouse thymocytes 
and human Nalm-6 cells. In thymocytes the level of bind- 
ing to these  substrates  was poor however was drastically 
enhanced  after Mn  2÷ treatment  of the cells.  The L1 anti- 
gen-coated polysterene beads were  able to bind to plate- 
lets and bend3 endothelioma cells expressing VLA-5. The 
binding to both substrates was dependent on L1 and could 
be blocked by mAbs to L1. Binding to platelets  was also 
inhibited by mAbs to VLA-5 and by the L1-RGD peptide 
whereas the binding to the endothelioma cells was clearly 
not affected. This was surprising since VLA-5 was detect- 
able at the luminal cell surface of endothelioma cells and 
was therefore accessible for the binding of the beads.  It is 
likely that in polarized cells like endothelial  cells VLA-5 
may be in different affinity states dependent on the locali- 
zation of the integrin (22). Cultured human endothelial cells 
express integrins including VLA-5 on the luminal and ba- 
solateral site however assemble fibronectin matrix at their 
basolateral surface (52). Also differentiated monocytic cells 
express two populations of fibronectin receptors: a minor- 
ity in a high affinity state and the majority in a low affinity 
state  (25).  This  could  explain  why in  endothelioma  cells 
the  VLA-5 was unable  to bind  to L1.  However,  the  L1- 
dependent binding of the beads observed suggested an ad- 
ditional ligand distinct from VLA-5 in these cells which has 
not yet been identified. 
Previously we characterized CD24 as a ligand for P-selec- 
tin on ESb-MP cells, granulocytes, and monocytes (2, 73). 
MAbs  to CD24 could block P-selectin-mediated  binding 
of myeloid cells to platelets or endothelioma cells in the cold 
(2).  In this  report  we show that  at  room temperature  or 
above CD24-specific mAbs could specifically enhance ho- 
motypic aggregation of ESb-MP cells by a VLA-5-L] path- 
way. The mechanism of this effect is presently unknown. It 
is likely that the slow spontaneous aggregation of ESb-MP 
cells is due to the previously described homotypic L1-L1 
interaction  (42, 50). The role of CD24 mAbs could be to 
activate an additional VLA-5-L1 heterotypic binding path- 
way leading to the observed enhanced cell clustering. Such 
activation of cell adhesiveness could happen by either stim- 
ulating the a5-integrin via signaling or by the induction of 
conformational changes in the VLA-5 integrin. Similar ac- 
tivation of fibronectin receptors including VLA-5 has been 
reported after treatment of cells with stem cell factor (49), 
mAbs to ICAM-3 (19) or CD9 (60). A  second possibility is 
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tional change of the L1 adhesion molecule. Indeed, studies 
by Kadmon  et  al.  (44)  have implicated  a  cis-interaction 
and functional cooperation of CD24 and L1 in neurones 
but not in B  lymphoblasts. Interestingly, recent structural 
studies  of integrin-ligand  interaction  have indicated  that 
amino acids adjacent to the integrin-binding sequence may 
be critical for ligand recognition (for review see reference 
32). A  given RGD site could be cryptic and only exposed 
after conformational changes. This concept of ligand acti- 
vation  emphazises  the  importance  of  local  secondary 
structure  and protein folding in regulating the functional 
state  of integrin  ligands.  We can not  exclude  at present 
whether such a model may be applicable to at least some 
forms of L1 or not. 
Evidence for a role of CD24 in the regulation of the cell 
adhesion comes also from other systems. In B lymphoblasts 
different mAbs to CD24 could either activate LFA-1--depen- 
dent cell aggregation (43) or could inhibit cell aggregation 
(42).  In a study on pre-B cell lines in which either CD24 
was inactivated by gene targeting or expression restored 
by transfection  it  was  shown  that  CD24  influenced  the 
avidity of a4-integrins (31,  45). In cells of the myeloid lin- 
eage CD24 appears to have two roles: a ligand for P-selec- 
tin and a signaling molecule for the activation of the VLA-5 
integrin. 
It is at present difficult to assess in which cellular inter- 
actions a  VLA-5-L1 binding could be involved. The role 
of VLA-5 has been studied in aspects of myeloid cell dif- 
ferentiation (8, 25), interaction with bone marrow stromal 
cells (72), the growth and differentiation of hematopoietic 
cells (6, 23, 78, 82), embryogenesis (87) and cell migration 
(7, 63) mainly focussing on the ability of this receptor to 
bind to fibronectin. Some reports have also described a po- 
tential function for VLA-5 in cell-cell interactions (5, 57). 
Since the L1 adhesion molecule is expressed by a wide va- 
riety of cells including  neural  cells,  intestinal  epithelium 
(81) and leukocytes (50), putative interactions with VLA-5 
being also expressed on many cells would be possible. At 
present we can not exclude that other integrins which are 
known to recognize the RGD sequence in a variety of ex- 
tracellular  matrix  proteins  may also  be  able  to  interact 
with the L1 adhesion molecule. It should also be mentioned 
that in contrast to the mouse the  human  L1  homologue 
has only one RGD site in the VI. Ig domain. At present we 
therefore can not extrapolate from our findings to the rote 
of L1 in other species. 
In the nervous system L1 is involved in granule neuron 
migration in the developing mouse cerebellar cortex (58), 
the fasciculation of neurites (27) and neurite outgrowth on 
other  neurites  and  Schwann  cells  (21,  74).  Neurite  out- 
growth in vitro can be stimulated by purified L1  (55), by 
transfected L1 expressed on monolayers of 3T3 fibroblasts 
(83) or with an L1-Fc-chimera in solution (24). Preincuba- 
tion of neurones  with antibodies  to L1  could inhibit  the 
stimulated  outgrowth  of neurites  implicating a  predomi- 
nantly  homotypic  L1-L1  interaction  (24).  Neurite  out- 
growth is influenced by the substrate and occurs also on 
extracellular matrix components (1,  11, 85) as well as on 
for example tissue sections of embryonic muscle where it 
is largely integrin-dependent (33). Expression of fibronec- 
tin receptors has been demonstrated in the mouse nervous 
system including some neurons (66). Although VLA-5 on 
the  nerve  growth  cone  has  not  formally  been  demon- 
strated, its expression is not unlikely since VLA-5 can par- 
ticipate in the endocytotic cycle and can be brought to the 
leading edge of a moving cell (14). It is therefore possible 
that neurite outgrowth on L1 substrate involves VLA-5 in- 
tegrin.  A  role of 131-integrins  (which includes VLA-5) in 
the neurite outgrowth on CAMs was indeed suggested in 
studies on TAG-1. TAG-1 is structurally related to L1 and 
comprises six Ig domains and four fibronectin type III re- 
peats with an RGD site located in the second repeat (28). 
Although TAG-1 can mediate homophilic binding, the neu- 
rite  outgrowth  on TAG-1  required  an  Ll-like molecule 
and  131-integrins  on the  neurites  (26).  Antibodies to ~31- 
integrins could block the neurite extension on TAG-1 sub- 
strate but not on NgCAM, a putative chick homologue to 
L1. These data do not support the assumption of an impor- 
tant  role  for the  VLA-5/L1  pathway in  neurite  growth. 
However,  structurally  NgCAM  and  L1  show  significant 
differences in  overall sequence  and  are  also different  in 
the localisation of RGD sequences (16). VLA-5 could be 
involved in cases where the growth of neurones is studied 
on other cells i.e. fibroblasts or neural cells. Fibroblasts do 
express VLA-5 and in earlier studies fibronectin receptors 
(likely to include VLA-5) were also shown to be expressed 
by neural cells (66). 
The signaling via CAMs like L1, N-CAM, or N-cadherin 
that ultimately leads to the growth of neuronal processes 
has been recently linked  to the FGF-receptors (84). The 
VLA-5 integrin has also been implicated, at least in part, 
to play a role in growth regulation (70). For tumor cells it 
has been shown that cells selected for low expression of 
a5131  are  more tumorigenic than  higher  expressors  (77) 
and that transfection of cx5131 into  CHO cells suppresses 
the growth, migration and tumorigenicity of these cells (29). 
The mechanism of this  growth regulation  is not entirely 
clear however may be related to the ligand occupancy of 
the VLA-5 integrin (70, 71). In a previous study we inves- 
tigated  the  tumorigenicity of L1 hi  and  L1 ~° subclones  of 
ESb-MP  in  syngeneic mice  (51).  We found that  animals 
bearing L11° subclone tumors died significantly earlier than 
L1 hi animals. The earlier death was due to a much faster 
growth of the primary tumor and an earlier onset of me- 
tastasis. The finding presented in this paper that L1  and 
VLA-5 are receptor and ligand on these cells that are used 
for homotypic cell interaction could be relevant to explain 
the tumor growth results. In this context it is interesting to 
note,  that  in  resting  lymphocytes after  the  induction  of 
proliferation in vivo or in vitro the L1 molecule is rapidly 
downregulated (35). This suggests that the VLA-5-L1 in- 
teraction may be more important in non-proliferating cells. 
In summary, we have shown that L1 adhesion molecule 
is  a  tigand  to VLA-5 integrin  and that  this newly estab- 
lished interaction may be important in diverse cell-cell in- 
teractions. 
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